Reversal of novel oral anticoagulants in patients with major bleeding

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 3, 2013, Pages 391-398

  Siegal, Deborah M ^a   Cuker, Adam ^b,c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Penn Comprehensive Hemophilia and Thrombosis Program   (United States)

Author keywords

Anticoagulant reversal; Apixaban; Bleeding; Dabigatran; Edoxaban; Rivaroxaban

Indexed keywords

ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; DABIGATRAN ETEXILATE; DESMOPRESSIN; ECARIN; EDOXABAN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN F(AB) FRAGMENT; PLACEBO; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBIN; TRANEXAMIC ACID;

BLEEDING; BLOOD CLOTTING TEST; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ECARIN CLOTTING TIME; EMBOLISM; HEART ATRIUM FIBRILLATION; HEMOCLOT ASSAY; HEMODIALYSIS; HEMOPERFUSION; HUMAN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THROMBIN TIME; THROMBOEMBOLISM; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; HEMORRHAGE; HEMOSTATICS; HUMANS; MALE; THROMBOEMBOLISM;

EID: 84876681725     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0885-0     Document Type: Conference Paper

References (65)

1. Gross PL, Weitz JI (2009) New antithrombotic drugs. Clin Pharmacol Ther 86(2):139-146
2. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292-303 (Pubitemid 47283865)
3. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36(2):386-399 (Pubitemid 351185753)
4. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 3(3):514-521. doi: 10.1111/j.1538-7836.2005.01166.x (Pubitemid 41632877)
5. Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC (2009) Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 101(4):780-782
6. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6(9):1542-1549. doi: 10.1111/j.1538-7836.2008.03064.x
7. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78(4):412-421. doi: 10.1016/j.clpt.2005.06.011 (Pubitemid 41393676)
8. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61(12):873-880 (Pubitemid 41803696)
9. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e44S-e88S
10. Bayer PHarma AG. Xarelto (2011) summary of product characteristics http://www.xarelto.com/html/downloads/Xarelto-Summary-of-Product- Characteristics-Dec2011.pdf Accessed 12 May 2012
11. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37(5):1056-1064. doi: 10.1124/dmd.108.025569
12. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37(1):74-81
13. Eriksson BI, Quinlan DJ, Weitz JI (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 48(1):1-22
14. Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C (2012) A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost 107(5):916-924. doi: 10.1160/TH11-09-0634
15. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, Lacreta F (2012) Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. doi: 10.1111/j.1365-2125.2012.04369.x
16. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50(7):743-753. doi: 10.1177/0091270009351883
17. Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S (2011) Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost 105(6):1080-1090. doi: 10.1160/TH10-11-0705
18. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W (2012) Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 126(20):2381-2391. doi: 10.1161/CIRCULATIONAHA.112.115410
19. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A (2012) Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 345:e7498. doi: 10.1136/bmj.e7498
20. FDA (2011) Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate), U.S. Food and Drug Administration http://www.fda.gov/drugs/ drugsafety/ucm282724.htm #. Accessed 7 May 2012
21. EudraVigilance Database, European Medicines Agency. http:// eudravigilance.ema.europa.eu/human/index.asp. Accessed 12 May 2012
22. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116-1127
23. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A (2011) Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 105(2):371-378
24. Freyburger G, Macouillard G, Labrouche S, Sztark F (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127(5):457-465
25. Stangier J, Feuring M (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23(2):138-143
26. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9(1):133-139
27. Barrett YC, Wang Z, Frost C, Shenker A (2010) Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104(6):1263-1271
28. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E (2010) Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 103(4):815-825
29. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107(2):379-387
30. Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49(5):761-772
31. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 6(5):820-829 (Pubitemid 351524543)
32. Van Ryn J, Litzenburger T, Waterman A, Canada K, Hauel N, Kroe-Barrett R, Singh S, Park J (2011) Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 57:E1130
33. van Ryn J, Litzenburger T, Gan G, Coble K, Schurer J (2012) In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran. ASH Annual Meet Abstr 120(21):3418
34. Toth J, Gan G, van Ryn J, Dursema H, Isler J, Coble K, Burke J, Lalovic B, Olson S (2012) Reversal of dabigatran's anticoagulant activity in the monkey by a specific antidote and pharmacokinetic and pharmacodynamic modeling. ASH Annual meet abstr 120(21):22
35. Lu G, DeGuzman FR, Lakhotia S, Hollenbach SJ, Phillips DR, Sinha U (2008) Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. ASH Annual Meet Abstr 112(11):983
36. Lu GP, Peng L, Hollenbach SJ, Abe K, DeGuzman FR, Siu G, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2009) Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 7:309
37. Hollenbach SJ, Lu G, Tan S, Lee G, Athiwat H, Inagaki M, Sinha U (2012) PRT064445 but not recombinant Fviia reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model. ASH Annual Meet Abstr 120(21):3414
38. Truumees E, Gaudu T, Dieterichs C, Geck M, Stokes J (2012) Epidural hematoma & intra-operative hemorrhage in a spine trauma patient on pradaxa (R) [Dabigatran]. Spine 37(14):E863-E865
39. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42(12):3594-3599
40. Morishima Y, Honda Y, Kamisato C, Furugohri T, Shibano T (2011) Reversal agents for edoxaban, a factor Xa inhibitor: effects of factor VIIa, anti-inhibitor coagulant complex, prothrombin complex concentrate, fresh plasma, and vitamin K. J Thromb Haemost 9:135
41. Narick C, Triulzi DJ, Yazer MH (2012) Transfusion-associated circulatory overload after plasma transfusion. Transfusion 52(1):160-165. doi: 10.1111/j.1537-2995.2011.03247.x
42. Toy P, Gajic O, Bacchetti P, Looney, Gropper MA, Hubmayr R, Lowell CA, Norris PJ, Murphy EL, Weiskopf RB, Wilson G, Koenigsberg M, Lee D, Schuller R, Wu P, Grimes B, Gandhi MJ, Winters JL, Mair D, Hirschler N, Sanchez Rosen R, Matthay MA, Group TS (2012) Transfusion-related acute lung injury: incidence and risk factors. Blood 119(7):1757-1767
43. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573-1579
44. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield W (2012) Prothrombin complex concentrates reduce blood loss in mice rendered coagulopathic by warfarin but not dabigatran etexilate. Transfusion 52:56A-57A
45. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116(1):94-102
46. Escolar G, Arellano-Rodrigo E, Reverter JC, Villalta J, Sanz V, Molina P, Diaz-Ricart M, Galan AM (2012) Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Circulation 126:520-521
47. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T (2012) Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 107(2):253-259
48. Hoffman MR, Volovyk Z, Monroe DM III (2012) Partial reversal of dabigatran effect by a prothrombin complex concentrate in a model of thrombin generation. ASH Annual Meet Abstr 120(21):3420
49. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 106(3):429-438
50. Key NS, Negrier C (2007) Coagulation factor concentrates: past, present, and future. Lancet 370(9585):439-448 (Pubitemid 47176658)
51. Gruber A, Marzec UM, Buetehorn U, Hanson S, Perzborn E (2008) Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. ASH Annual Meet Abstr 112(11):3825
52. Perzborn E, Tinel H (2008) FEIBA reverses the effects of a high-dose of rivaroxaban in rats. Pathophysiol Haemost Thromb 36:A40
53. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217-224
54. Chan HHW, Atkinson HM, Goncharenko M, Berry LR, Chan AKC (2011) Reversal of dabigatran using recombinant activated factor VII and activated prothrombin complex concentrates in thromboelastography assay. J Thromb Haemost 9:576-577
55. Ehrlich HJ, Henzl MJ, Gomperts ED (2002) Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 8(2):83-90 (Pubitemid 35238060)
56. Aledort LM (2004) Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2(10):1700-1708 (Pubitemid 40192708)
57. Wolzt M, Levi M, Sarich TC, Bostrom SL, Eriksson UG, Eriksson-Lepkowska M, Svensson M, Weitz JI, Elg M, Wahlander K (2004) Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 91(6):1090-1096 (Pubitemid 38821264)
58. Levi M, Levy JH, Andersen HF, Truloff D (2010) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363(19):1791-1800
59. Stangier J, Rathgen K, Stahle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259-268
60. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G (2012) Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 46(9):e21. doi: 10.1345/aph.1R081
61. Lange J, Thiel C, Thiel K, Klingert W, Klingert K, Konigsrainer A, Formella S, Clemens A, van Ryn J, Schenk M (2012) Acceleration of dabigatran elimination by activated charcoal perfusion and hemodialysis in a pig model. ASH Annual Meet Abstr 120(21):2272
62. Bristol-Myers Squibb. Eliquis Product Monograph (2011) http://www.bmscanada.ca/static/products/en/pm-pdf/Eliquis-EN-PM.pdf. Accessed 12 May 2012
63. Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabro MG, Ranucci M, Zangrillo A (2008) Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology 109(6):1063-1076. doi: 10.1097/ALN.0b013e31818db18b
64. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane database of systematic rev. (3):CD001886. doi: 10.1002/14651858.CD001886.pub4
65. Siegal DM, Crowther MA (2012) Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. doi: 10.1093/eurheartj/ehs408